Skip to main content
SpringerLink
Log in
Book cover

Tumor Microenvironment pp 39–53Cite as

Syndecan-1 in the Tumor Microenvironment

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1272))

Abstract

Syndecan-1 along with the other three syndecan proteins is present in the varied components of the tumor microenvironment: fibroblasts, inflammatory tumor immunity-associated cells, vessels, and extracellular matrix. Epithelial and non-epithelial tumors may show stromal syndecans. The main relevance of stromal syndecans as tumor biomarker resides in the relationships to tumor features such as type and differentiation as well as to prognosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ahmed Haji Omar A, Haglund C, Virolainen S, Häyry V, Atula T, Kontio R, Rihtniemi J, Pihakari A, Salo T, Hagström J, Sorsa T (2013) Epithelial and stromal syndecan-1 and -2 are distinctly expressed in oral- and cutaneous squamous cell carcinomas. J Oral Pathol Med 42(5):389–395

    Article  PubMed  Google Scholar 

  2. Alaeddini M, Yazdani F, Etemad-Moghadam S (2019) Stromal and epithelial syndecan-1 expression in benign and malignant salivary gland tumors: which is more reflective of behavior? Braz J Otorhinolaryngol S1808-8694(19):30091–30096

    Google Scholar 

  3. Al-Shibli K, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Busund LT (2010) The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma. APMIS 118(5):371–382

    Article  PubMed  Google Scholar 

  4. Barbareschi M, Maisonneuve P, Aldovini D, Cangi MG, Pecciarini L, Angelo Mauri F, Veronese S, Caffo O, Lucenti A, Palma PD, Galligioni E, Doglioni C (2003) High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98(3):474–483

    Article  PubMed  Google Scholar 

  5. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS (2001) Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod Pathol 14(10):1052–1058

    Article  CAS  PubMed  Google Scholar 

  6. Charchanti A, Papoudou Bai A, Samantas E, Papakostas P, Skarlos P, Kanavaros P, Ntritsos G, Agnantis JN, Goussia AC (2019) Association of low Syndecan-1 expression with adverse histopathological parameters in gastric carcinomas. J BUON 24(3):1106–1112

    PubMed  Google Scholar 

  7. Conklin MW, Gangnon RE, Sprague BL, Van Gemert L, Hampton JM, Eliceiri KW, Bredfeldt JS, Liu Y, Surachaicharn N, Newcomb PA, Friedl A, Keely PJ, Trentham-Dietz A, Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ. Cancer Epidemiol Biomarkers Prev. 2018 ;27(2):138–145.

    Google Scholar 

  8. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC (2004) Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10(15):5178–5186

    Article  CAS  PubMed  Google Scholar 

  9. Götte M, Kersting C, Ruggiero M, Tio J, Tulusan AH, Kiesel L, Wülfing P (2006) Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 26(1B):621–627

    PubMed  Google Scholar 

  10. Hasengaowa KJ, Kusumoto T, Shinyo Y, Seki N, Hiramatsu Y (2005) Prognostic significance of syndecan-1 expression in human endometrial cancer. Ann Oncol 16(7):1109–1115

    Article  CAS  PubMed  Google Scholar 

  11. Kind S, Jaretzke A, Büscheck F, Möller K, Dum D, Höflmayer D, Hinsch A, Weidemann S, Fraune C, Möller-Koop C, Hube-Magg C, Simon R, Wilczak W, Lebok P, Witzel I, Müller V, Schmalfeldt B, Paluchowski P, Wilke C, Heilenkötter U, von Leffern I, Krech T, Krech RH, von der Assen A, Bawahab AA, Burandt E (2019) A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. Mol Carcinog 58(12):2306–2315

    Article  CAS  PubMed  Google Scholar 

  12. Lendorf ME, Manon-Jensen T, Kronqvist P, Multhaupt HA, Couchman JR (2011) Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma. J Histochem Cytochem 59(6):615–629

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Liakou E, Mavrogonatou E, Pratsinis H, Rizou S, Evangelou K, Panagiotou PN, Karamanos NK, Gorgoulis VG, Kletsas D (2016) Ionizing radiation-mediated premature senescence and paracrine interactions with cancer cells enhance the expression of syndecan 1 in human breast stromal fibroblasts: the role of TGF-β. Aging (Albany NY) 8(8):1650–1669

    Article  CAS  Google Scholar 

  14. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C (2004) Prognostic value of syndecan-1 expression in breast cancer. Oncology 67(1):11–18

    Article  CAS  PubMed  Google Scholar 

  15. Lim GH, Tan PH, Jara-Lazaro AR, Thike AA, Sim WC, Yap VB, Yip GW (2014) Syndecan-1 is a potential biomarker for triple-positive breast carcinomas in Asian women with correlation to survival. Singap Med J 55(9):468–472

    Article  Google Scholar 

  16. Lohr M, Edlund K, Botling J, Hammad S, Hellwig B, Othman A, Berglund A, Lambe M, Holmberg L, Ekman S, Bergqvist M, Pontén F, Cadenas C, Marchan R, Hengstler JG, Rahnenführer J, Micke P (2013) The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 333(2):222–228

    Article  CAS  PubMed  Google Scholar 

  17. Loussouarn D, Campion L, Sagan C, Frenel JS, Dravet F, Classe JM, Pioud-Martigny R, Berton-Rigaud D, Bourbouloux E, Mosnier JF, Bataille FR, Campone M (2008) Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br J Cancer 98(12):1993–1998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Máthé M, Suba Z, Németh Z, Tátrai P, Füle T, Borgulya G, Barabás J, Kovalszky I (2006) Stromal syndecan-1 expression is an adverse prognostic factor in oral carcinomas. Oral Oncol 42(5):493–500

    Article  PubMed  Google Scholar 

  19. Maeda T, Alexander CM, Friedl A (2004) Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res 64(2):612–621

    Article  CAS  PubMed  Google Scholar 

  20. Mennerich D, Vogel A, Klaman I, Dahl E, Lichtner RB, Rosenthal A, Pohlenz HD, Thierauch KH, Sommer A (2004) Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumours. Eur J Cancer 40(9):1373–1382

    Article  CAS  PubMed  Google Scholar 

  21. Mitselou A, Galani V, Skoufi U, Arvanitis DL, Lampri E, Ioachim E (2016) Syndecan-1, Epithelial-Mesenchymal Transition Markers (E-cadherin/β-catenin) and Neoangiogenesis-related Proteins (PCAM-1 and Endoglin) in Colorectal Cancer. Anticancer Res 36(5):2271–2280

    CAS  PubMed  Google Scholar 

  22. Mukunyadzi P, Liu K, Hanna EY, Suen JY, Fan CY (2003) Induced expression of syndecan-1 in the stroma of head and neck squamous cell carcinoma. Mod Pathol 16(8):796–801

    Article  PubMed  Google Scholar 

  23. Nguyen TL, Grizzle WE, Zhang K, Hameed O, Siegal GP, Wei S (2013) Syndecan-1 overexpression is associated with nonluminal subtypes and poor prognosis in advanced breast cancer. Am J Clin Pathol 140(4):468–474

    Article  PubMed  Google Scholar 

  24. Orecchia P, Conte R, Balza E, Petretto A, Mauri P, Mingari MC, Carnemolla B (2013) A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma. Eur J Cancer 49(8):2022–2033

    Article  CAS  PubMed  Google Scholar 

  25. Palaiologou M, Delladetsima I, Tiniakos D (2014) CD138 (syndecan-1) expression in health and disease. Histol Histopathol 29(2):177–189

    CAS  PubMed  Google Scholar 

  26. Roskams T, De Vos R, David G, Van Damme B, Desmet V (1998) Heparan sulphate proteoglycan expression in human primary liver tumours. J Pathol 185(3):290–297

    Article  CAS  PubMed  Google Scholar 

  27. Sanderson RD, Yang Y (2008) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin Exp Metastasis 25(2):149–159

    Article  CAS  PubMed  Google Scholar 

  28. Stanley MJ, Stanley MW, Sanderson RD, Zera R (1999) Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 112(3):377–383

    Article  CAS  PubMed  Google Scholar 

  29. Sharpe B, Alghezi DA, Cattermole C, Beresford M, Bowen R, Mitchard J, Chalmers AD (2017) A subset of high Gleason grade prostate carcinomas contain a large burden of prostate cancer syndecan-1 positive stromal cells. Prostate 77(13):1312–1324

    Article  CAS  PubMed  Google Scholar 

  30. Su G, Blaine SA, Qiao D, Friedl A (2007) Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J Biol Chem 282(20):14906–14915

    Article  CAS  PubMed  Google Scholar 

  31. Szarvas T, Reis H, Kramer G, Shariat SF, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübben H (2014) Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. Hum Pathol 45(4):674–682

    Article  CAS  PubMed  Google Scholar 

  32. Wiksten JP, Lundin J, Nordling S, Lundin M, Kokkola A, von Boguslawski K, Haglund C (2001) Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer 95(1):1–6

    Article  CAS  PubMed  Google Scholar 

  33. Yang N, Mosher R, Seo S, Beebe D, Friedl A (2011) Syndecan-1 in breast cancer stroma fibroblasts regulates fiber organization and carcinoma cell motility. Am J Pathol 178(1):325–335

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d’Anatomie pathologique; APHP GHU Avicenne, University Sorbonne Paris Nord, Bobigny, France

    Adriana Handra-Luca

Authors
  1. Adriana Handra-Luca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adriana Handra-Luca .

Editor information

Editors and Affiliations

  1. Department of Radiology, Columbia University Medical Center, New York, NY, USA, Department of Pathology, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil

    Alexander Birbrair

Rights and permissions

Reprints and permissions

Copyright information

© 2020 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Handra-Luca, A. (2020). Syndecan-1 in the Tumor Microenvironment. In: Birbrair, A. (eds) Tumor Microenvironment . Advances in Experimental Medicine and Biology, vol 1272. Springer, Cham. https://doi.org/10.1007/978-3-030-48457-6_3

Download citation

Publish with us

Policies and ethics

Search

Navigation